Selecting platelets for transfusion of the alloimmunized patient: A review

Immunohematology

Volumn 14, Issue 3, 1998, Pages 117-123

  Mrrpirv, S ^a,b   Varma, M ^a  

^a AMERICAN RED CROSS BLOOD SERVICES   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; HLA ANTIGEN;

ALLOIMMUNIZATION; BLOOD COMPONENT THERAPY; ERYTHROCYTE ADHESIVENESS; HLA TYPING; HUMAN; LYMPHOCYTOTOXICITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION;

EID: 0031683867     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Meryman HT. Transfusion-induced alloimmunization and immunosuppression and the effects of leukocyte depletion.Transfus Med Rev 1989:3:180.
2. Dzik WH. Leukoreduced blood components: laboratory and clinical aspects. In Rossi EC, Simon TL, Moss GS,et al.,eds. Principles of transfusion medicine. 2nd ed. Baltimore:Williams and Wilkins, 1996: 353-73-
3. The Trial to Reduce Alloimmunization to Platelets (TRAP) study group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N EnglJ Med 1997;337:186l-9.
4. Sintnicolaas K, van Marwijk Kooij M, Van Prooigen HC, et al. Leukocyte depletion of random singledonor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995;85:824-8.
5. Bishop JF, McGrath K,Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-7.
6. Friedberg RC, Donnelly SF, Boyd JC, et al. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993:81: 3428-34.
7. Klumpp TR, Herman J, Innis S, et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 1996:17:1035-41.
8. Doughty HA, Murphy MR Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness.Vox Sang 1994;66:200-5.
9. Alcorta 1, Pereira A, Ordinas A. Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Br J Haematol 1996;93: 220-4.
10. Bock M, Muggenthaler KH, Schmidt U, et al. Influence of antibiotics on post-transfusion platelet incremem.Transfusion 1996:36:952-4.
11. Dutcher JP, Schiffer CA, Aisner J, et al. Long-term follow-up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood 1981:58:1007-11.
12. Hogge DE, Dutcher JP Aisner J, et al. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 1983:14:363-9.
13. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA Class I allo-antibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994:39:272-80.
14. Duquesnoy RJ, Filip DJ, Rodey GE. el al. Successful transfusion of platelets "mismatched1' for HLA antigens to alloimmunized thrombocytopenic patients. AmJ Hematol 1977:2:219-26.
15. MacPherson BR, Hammond PB, Maniscalco CA. Alloimmunization to public HIA antigens in multitransfused platelet recipients. Ann Clin & Lab Science 1986; 16:38-44.
16. Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusion in alloimmnnixed patients. Blood 1987;70:1727-9.
17. Yankee RA,Grumet FC. Rogentine (IN. Platelet transfusion. The selection of compatible platelet donors for refractor)- patients by lymphocyte HLA typing. N EnglJMed 1969:281:1208-12.
18. Uahlke MB. Weiss KL. Platelet transfusion from donors mismatched for cross reactive HLA antigens. Transfusion 1984;24:299-302.
19. Rachel JM. Summers TC, Sinor LT. et al. Lise of a solid phase red blood cell adherence method for pretransmsion platelet compatibility testing. Am J Clin Pathol 1988:90:63-8.
20. Gelb AB, Leavitt AD. Crossmatch-compatible platelets improve corrected count increments in patients who arc refractory to randomly selected platelets. Transfusion 1997;37:624-30.
21. Petz ID. Garratty G, Clark BD, et al.The effectiveness of an antibody specificity prediction (ASP) method for selecting platelets for transfusion to alloimmunized patients (abstract). Blood 199>;86:546a.